Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4262540 | 0.93 | ROCK2 (0.41) | ROCK2KDM4EALDH1A1MAPTGPR6 | |
| Trifluoroacetic Acid SCHEMBL1655979 | 0.93 | ROCK2 (0.39) | ROCK2KDM4EALDH1A1MAPTGPR6 | |
| Trifluoroacetic Acid SCHEMBL4263955 | 0.91 | ALDH1A1 (0.38) | ROCK2ACHEALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1656585 | 0.91 | ROCK2 (0.35) | ROCK2CNR1 | |
| SCHEMBL6793479 | 0.89 | ROCK2 (0.38) | ROCK2ACHECHRM2KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4262242 | 0.87 | ADRB3 (0.37) | ROCK2NPC1 | |
| Trifluoroacetic Acid SCHEMBL4263853 | 0.87 | ROCK2 (0.37) | ROCK2MAPT | |
| Trifluoroacetic Acid SCHEMBL1655450 | 0.87 | NAMPT (0.41) | ROCK2 | |
| Trifluoroacetic Acid SCHEMBL1656607 | 0.86 | CDK2 (0.36) | ROCK2 | |
| Trifluoroacetic Acid SCHEMBL4263119 | 0.86 | ROCK2 (0.39) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | ROCK2 317/4885ACHE 3673/4885CHRM2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.